Quantcast

Latest Alkaloids Stories

2009-06-08 21:45:58

Cremophor-containing paclitaxel, a drug used in treating cancer, has been associated with allergic reactions, some fatal, U.S. researchers said. Researchers at Northwestern University Feinberg School of Medicine identified 287 unique cases of hypersensitivity reactions submitted to the FDA's Adverse Event Report System from 1997-2007, with 109 deaths in patients who received Cremophor-based paclitaxel, a solvent-administered taxane chemotherapy. Adverse event reports generally only represent...

2009-06-08 13:22:19

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.A new study from the Research on Adverse Drug Events and Reports (RADAR) pharmacovigilance program at Northwestern University Feinberg School of Medicine identified 287 unique cases of hypersensitivity reactions submitted to the FDA's Adverse Event Report System between 1997 and 2007 with 109 (38 percent) deaths in patients who received...

2009-06-03 07:02:00

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer - - Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment - - Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could...

2009-06-03 00:30:00

Promising Preliminary Results on Radiation Sensitization from Phase II Trial May Serve as Additional Registration Direction for OPAXIO ORLANDO, Fla., June 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that, in a study released from Brown University at the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting, patients with cancer of the lower esophagus had evidence of a high pathological complete response ("CR") rate when given...

2009-06-01 08:00:00

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and TUSTIN, Calif., June 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that preliminary results from a Phase II trial of its lead anti-phosphatidylserine antibody...

2009-06-01 07:00:00

MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. (Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) "We are delighted with the depth and breadth of the data available on our lead...

2009-05-30 15:31:00

Webcast at 7:10 p.m. Eastern Time Today BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the final results of a Randomized Phase 2 Trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Analyses indicated a survival benefit in patients treated with OGX-011 in combination with docetaxel compared to docetaxel alone - the current standard care for patients with...

2009-05-28 07:00:00

- New Progression-Free Survival Data To Be Presented at 2009 ASCO Annual Meeting Support Further Clinical Development of Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Poniard Management Team to Host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused...

2009-05-27 08:30:00

- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer - - Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types - TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that data from two ongoing...

2009-05-27 08:19:49

Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.A national study led by William Gradishar, M.D., director of breast medical oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, found that the drug Abraxane prolonged progression-free survival...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related